Last reviewed · How we verify
Intensive treatment with sodium bicarbonate
Intensive treatment with sodium bicarbonate is a pH modulator / alkalinizing agent Small molecule drug developed by University of Roma La Sapienza. It is currently FDA-approved for Solid tumors (investigational approach to enhance chemotherapy and reduce tumor acidosis).
Sodium bicarbonate raises blood and tissue pH to create an alkaline environment that may inhibit tumor growth and enhance chemotherapy efficacy.
Sodium bicarbonate raises blood and tissue pH to create an alkaline environment that may inhibit tumor growth and enhance chemotherapy efficacy. Used for Solid tumors (investigational approach to enhance chemotherapy and reduce tumor acidosis).
At a glance
| Generic name | Intensive treatment with sodium bicarbonate |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Drug class | pH modulator / alkalinizing agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Intensive sodium bicarbonate treatment works by systemic alkalinization, which counteracts the acidic microenvironment typical of solid tumors. The alkaline pH is hypothesized to reduce tumor cell proliferation, enhance drug penetration, and improve oxygenation. This approach is based on the observation that cancer cells thrive in acidic conditions and may be suppressed by pH normalization.
Approved indications
- Solid tumors (investigational approach to enhance chemotherapy and reduce tumor acidosis)
Common side effects
- Metabolic alkalosis
- Hypernatremia
- Hypokalemia
- Nausea
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Honey or Olive Oil for Treating Oral Mucositis in Children and Adults With Leukemia Receiving Intensive Chemotherapy (PHASE1)
- N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive treatment with sodium bicarbonate CI brief — competitive landscape report
- Intensive treatment with sodium bicarbonate updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI
Frequently asked questions about Intensive treatment with sodium bicarbonate
What is Intensive treatment with sodium bicarbonate?
How does Intensive treatment with sodium bicarbonate work?
What is Intensive treatment with sodium bicarbonate used for?
Who makes Intensive treatment with sodium bicarbonate?
What drug class is Intensive treatment with sodium bicarbonate in?
What development phase is Intensive treatment with sodium bicarbonate in?
What are the side effects of Intensive treatment with sodium bicarbonate?
Related
- Drug class: All pH modulator / alkalinizing agent drugs
- Manufacturer: University of Roma La Sapienza — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Solid tumors (investigational approach to enhance chemotherapy and reduce tumor acidosis)
- Compare: Intensive treatment with sodium bicarbonate vs similar drugs
- Pricing: Intensive treatment with sodium bicarbonate cost, discount & access